Today: 30 June 2026
Browse Category

NYSE:PFE 11 May 2026 - 30 June 2026

Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus

Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus

Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%. It’s really about scale for investors. Reuters said sales of GLP-1 drugs on Alibaba and JD.com sites hit around 1.4 billion yuan in Q1, using Jefferies numbers. That would be about $828 million a year through those e-commerce channels. Meanwhile, Pfizer’s annualized dividend payout based on $0.43 per share and 5.731 billion Q1 diluted shares comes to almost $9.9 billion.
30 June 2026
··
Pfizer (NYSE:PFE) yield math back in focus after cancer drug miss, shares recover Friday

Pfizer (NYSE:PFE) yield math back in focus after cancer drug miss, shares recover Friday

U.S. cash stock trading was closed Sunday. The New York Stock Exchange posts regular hours of 9:30 a.m. to 4:00 p.m. ET, and says its next holiday for 2026 is Independence Day, observed Friday, July 3. Pfizer’s last trade was Friday’s close. Pfizer Inc. finished Friday at $24.29, up 62.5 cents after dipping as low as $23.70 during the day. About 60 million shares changed hands. The stock had dropped for six sessions in a row, ending Thursday at $23.67.
28 June 2026
···
Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed

Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed

Pfizer Inc. opens Thursday carrying a clearer income pitch, but growth looks shaky. Shares have slid, sending the dividend yield above 7%. The company scored an FDA win for Ibrance, its established breast cancer drug. But sigvotatug vedotin, a lung cancer antibody-drug conjugate from the Seagen deal, failed in late-stage testing. U.S. markets weren’t open yet in New York. NYSE starts core trading at 9:30 a.m. ET until 4 p.m. ET, and June 25 isn’t listed as a 2026 holiday on the exchange. Pfizer last traded at $24.09 in premarket at 08:53 EDT, compared to Wednesday’s close of $24.04.
25 June 2026
·
Pfizer (NYSE:PFE) churns as investors price in bigger cancer pipeline discount after Seagen drug miss

Pfizer (NYSE:PFE) churns as investors price in bigger cancer pipeline discount after Seagen drug miss

Pfizer traded near flat in early premarket hours on Wednesday after a round of heavy selling that didn’t move the price much. Shares were at $24.76 at 7:07 a.m. EDT, just 0.16% higher than Tuesday’s $24.72 close. The stock is down about 14% from its 52-week high and up around 7% from its low. Pfizer shares ended down 1.44% on Tuesday. Volume was huge, with 81.9 million shares traded—well above the 50-day average of 36.8 million. Notional turnover at the close was about $2.0 billion, a lot for just one day tied to a clinical update. The S&P 500 dropped 1.44% too, but Pfizer trailed rival drugmakers: Johnson & Johnson gained 3.37%, Eli Lilly added 0.45%.
24 June 2026
·
Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal

Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal

Pfizer Inc. shares fell on Tuesday. The company said a key lung cancer drug from its Seagen unit didn’t hit the main endpoint in a late-stage study. That’s another setback for Pfizer as it tries to spark growth again after its COVID-era products. Pfizer shares slipped 0.8% to $24.89 in afternoon trading. The Health Care Select Sector SPDR ETF gained 1.3%. The SPDR S&P 500 ETF Trust dropped roughly 1%, and Pfizer lagged the health-care sector as the wider market also fell. Merck, which will have its Keytruda in Pfizer’s next trial of the drug, rose 2.9%.
23 June 2026
··
Pfizer (NYSE:PFE) stock pinned near CFO-exit selloff as investors wait for proof on growth

Pfizer (NYSE:PFE) stock pinned near CFO-exit selloff as investors wait for proof on growth

Pfizer Inc entered Monday pinned near last week’s selloff, with investors still weighing the planned departure of finance chief Dave Denton against the company’s promise of post-2028 growth. For NYSE:PFE, the timing matters. Regular NYSE trading had not opened at the dateline time; the exchange’s core session runs from 9:30 a.m. to 4:00 p.m. ET, and Friday was a Juneteenth market holiday, making Thursday’s reaction the last full trading signal.
22 June 2026
·
Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands

Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands

Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend. Dave Denton has been a key figure pitching Pfizer’s post-COVID plan to Wall Street—cutting costs after weaker pandemic sales, adding big deals, and leaning on a pipeline with unproven strength. Pfizer said Denton will leave Aug. 15. Cecile Guegan steps in as interim CFO the next day while Pfizer looks inside and outside for a replacement. CEO Albert Bourla called Denton a “steady and trusted steward.” Denton said Pfizer is “in excellent hands.”
21 June 2026
··
Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dip after CFO departure raises new questions about 2026 outlook

Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth. That’s what investors head into next week with. Pfizer isn’t only swapping finance chiefs; the company is making the change as it works to prove its deals, cuts, and fresh drugs are enough to offset weaker COVID vaccine and antiviral demand.
19 June 2026
··
Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild. The shares were down 83 cents, or about 3.2%, at $25.09 around 11:42 a.m. EDT. That compared with a roughly 0.6% rise in the SPDR S&P 500 ETF Trust, a widely used tracker of the S&P 500 index.
18 June 2026
··
Pfizer trades up with Rigel’s Veppanu deal done

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed. Dow sets a record, Pfizer edges higher as tech lags Pfizer finished at $26.04, up 0.15%. The S&P 500 slipped 0.57% and the Nasdaq lost 1.15%. The Dow gained 0.64% for a record close, lifted as money rotated out of tech stocks into other sectors.
17 June 2026
·····
Pfizer Holds Near $26, Dividend Draws Watch as Drug Prices Cloud Outlook

Pfizer Holds Near $26, Dividend Draws Watch as Drug Prices Cloud Outlook

Pfizer Inc. ended the U.S. session at $26.21, up 4 cents. Volume was around 38.8 million shares and market cap was close to $150.2 billion. Shares barely budged even as the S&P 500 gained 0.50% and the Dow added 0.70%, according to market data. Pfizer’s trailing P/E hovered near 20. PFE’s main near-term draw is income. Pfizer’s board kept the dividend at $0.43 for the second quarter, payable June 12 to holders of record on May 8. That keeps the streak alive at 350 straight quarters. The stock ended Friday at $26.21, giving the $1.72 annual payout a yield near 6.6%. That’s annual dividends divided by share price. The high yield helps support the shares, with growth prospects still limited. It also keeps focus on Pfizer’s cash flow.
15 June 2026
···
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer Inc. closed Friday at $26.21, up 4 cents. About 38.77 million shares changed hands. Market cap came in near $149.38 billion. Gains were small against the major indexes. The S&P 500 added 0.5%, Dow rose 0.7%, and Nasdaq was up 0.3%. The Health Care Select Sector SPDR ETF dropped 0.18%. Pfizer still outperformed its sector benchmark. Drug pricing in Europe is back in focus for investors. Germany’s health minister, Nina Warken, said drug companies won’t be left out of upcoming cost cuts, telling reporters, “Every sector must play its part in this reform.” That comment came after a Reuters story said Pfizer CEO Albert Bourla told Chancellor Friedrich Merz the company is “reviewing our external engagements as well as the timing, scope and future prioritization” of some planned investments in Germany. For stocks, the story is simple: shares go up on hopes for better profits or less risk, and drop when rules, failed trials, or weaker pricing hit cash flow.
13 June 2026
····
Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Still Trades Over $26 as RBC Lift Balances Out Drug-Pricing Concerns

New York, June 12, 2026, 11:50. Pfizer Inc. shares added 0.36% to trade around $26.27 Friday, putting its market cap at roughly $150.5 billion. The stock had climbed 2.23% Thursday, closing at $26.17, on higher-than-average volume and outperforming most major health-care names, MarketWatch said. Broader markets were higher Friday, with the SPDR S&P 500 ETF Trust up, but the Health Care Select Sector SPDR ETF was down a bit, showing Pfizer trading better than the sector in late-morning deals.
12 June 2026
··
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

Dow, S&P 500 edge up, Nasdaq slips in midday trade U.S. stocks were mixed late Tuesday morning. The Dow and S&P 500 held small gains, while the Nasdaq slipped after a rebound in artificial-intelligence shares and ahead of another inflation readout this week. Delayed LSEG data from Reuters showed the S&P 500 up 0.22% at 7,421.81, the Dow up 0.30% at 50,940.88, and the Nasdaq down 0.03% at 25,921.29. Wall Street is looking to recover after tech stocks dropped hard late last week. Now investors are waiting for May’s Consumer Price Index from the Labor Department, expected at 8:30 a.m. EDT Wednesday.
9 June 2026
·········
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Inc. shares fell in premarket trading Tuesday after the FDA cleared a new label for its hemophilia treatment Hympavzi. Investors are still sizing up the company’s longer path to profits in obesity drugs. The stock traded at $25.62, off 43 cents, or 1.7%. Pfizer is in focus this week with two key stories: one is a short-term regulatory approval in the rare-disease space, the other is a bigger, higher-risk push into obesity with a once-monthly shot that could drive growth as its older drugs face LOE. Loss of exclusivity exposes branded drugs to copycats when patent or regulatory shields drop.
9 June 2026
··
Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Inc. heads into Monday’s open with investors facing a heavier cancer-drug news tape than its stock price showed last week, after fresh oncology data at the American Society of Clinical Oncology meeting and a China partnership worth up to $10.5 billion. The timing matters. U.S. trading was shut Sunday, and the previous week was shortened by the Memorial Day closure on Monday; the NYSE’s core session runs from 9:30 a.m. to 4 p.m. ET. That leaves Monday as the first full market test for most of the weekend ASCO data.
31 May 2026
·
Pfizer Faces Busy Week After Friday’s Drop

Pfizer Faces Busy Week After Friday’s Drop

Pfizer Inc. is starting the week stuck after shares fell Friday. Investors have yet to see if a better quarter is enough for ongoing growth. With U.S. markets shut over the weekend, PFE last traded at $25.33 on Friday. Stocks slid Friday as macro worries returned. The S&P 500, Dow, and Nasdaq all lost more than 1%. Treasury yields moved higher again, adding to the pressure as bonds drew more interest and stock valuations tightened.
17 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc is looking to expand in India, focusing on cancer drugs, obesity therapies, vaccines and other specialty medicines as it looks to get back on track after its COVID-19 sales surge faded. Meenakshi Nevatia, who heads Pfizer in India, called the country a “must-win” and said “no company can be global if they’re not winning.” Nevatia also pointed to the need for faster product launches and better pricing for the Indian market. Pfizer is trying to reassure investors as it moves past the COVID boom and braces for patent expirations. First-quarter revenue came in at $14.5 billion, 5% higher than last year. When stripping out older drugs, sales from new and acquired medicines rose 22% on an operational basis. Pfizer expects to lose about $1.5 billion in sales this year from generic and biosimilar competition.
15 May 2026
·
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Acuitas Therapeutics has failed in its attempt to shield Pfizer Inc. and BioNTech’s Comirnaty COVID-19 vaccine from GSK’s patent claims, after a Delaware federal judge tossed the case. Judge Gregory Williams sided with GSK’s subsidiaries, dismissing the Acuitas action for lack of subject-matter jurisdiction. In effect, the court said it didn’t have the authority to hear the suit as filed, leaving the broader patent dispute over the high-profile vaccine unresolved. The ruling stops short of saying if Comirnaty actually infringes on GSK’s patents. For Pfizer, that distinction is pressing: the company is working to steer investors’ attention away from its COVID lineup and onto potential growth in cancer, blood thinners, and obesity drugs, especially in the wake of a sharp sales reset during the pandemic.
11 May 2026
··
1 2 3 … 11

Stock Market Today

  • Oil Prices Head for Sharpest Quarterly Drop Since 2018 as Supply Pressures Fade
    June 30, 2026, 2:52 PM EDT. Oil prices are set for their biggest quarterly fall in six years as supply strain eases. Shippers are finding ways around the Strait of Hormuz, which had been a major hurdle for oil flows, and Chinese crude imports have pulled back, softening the hit from reduced Persian Gulf exports. The moves have helped unwind tightness in oil markets, sending prices lower.
Go toTop